Tags

Type your tag names separated by a space and hit enter

Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
Ann Pharmacother. 2010 Mar; 44(3):415-23.AP

Abstract

BACKGROUND

Previous studies have shown conflicting results on low-density lipoprotein cholesterol (LDL-C) reduction for comparable doses of pitavastatin and atorvastatin.

OBJECTIVE

To compare the efficacy of pitavastatin 1 mg once daily with that of atorvastatin 10 mg once daily on lipoprotein change, safety, and cost per percent LDL-C reduction.

METHODS

An 8-week, randomized, open-label, parallel trial was conducted in patients with hypercholesterolemia. One hundred patients were equally randomized to receive pitavastatin 1 mg once daily or atorvastatin 10 mg once daily; 98 completed the study. Outcomes were assessed at baseline and at the end of the study.

RESULTS

Pitavastatin lowered LDL-C levels from baseline by 37% compared with 46% in the atorvastatin group (p < 0.001). The reduction of total cholesterol (TC) levels from baseline was significantly different between the pitavastatin (28%) and atorvastatin (32%) groups (p = 0.005). There was no significant difference in the percentage of changes in triglyceride and high-density lipoprotein cholesterol levels between groups. The percentage of patients who achieved LDL-C goals according to National Cholesterol Education Program-Adult Treatment Panel III guidelines was not significantly different between the pitavastatin (74%) and atorvastatin (84%) groups (p = 0.220). In addition, both regimens were well tolerated, with no patient developing an elevation of more than 3 times the upper normal limit of alanine aminotransferase or 10 times that of creatine kinase. The monthly cost per percent LDL-C reduction in the pitavastatin group ($0.77) was about 50% lower than the cost in the atorvastatin ($1.56) group.

CONCLUSIONS

Although pitavastatin 1 mg daily was not as effective at lowering LDL-C and TC levels as atorvastatin 10 mg daily, the number of patients achieving their LDL-C goals with pitavastatin was comparable with the number using atorvastatin. Pitavastatin 1 mg once daily may be an alternative regimen with cost-saving benefits but without a significant decrease in therapeutic benefit or increase in adverse events in patients with hypercholesterolemia.

Authors+Show Affiliations

Division of Cardiology, Department of Internal Medicine, Phramongkutklao Hospital, Bangkok, Thailand.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

20179259

Citation

Sansanayudh, Nakarin, et al. "Comparative Efficacy and Safety of Low-dose Pitavastatin Versus Atorvastatin in Patients With Hypercholesterolemia." The Annals of Pharmacotherapy, vol. 44, no. 3, 2010, pp. 415-23.
Sansanayudh N, Wongwiwatthananukit S, Putwai P, et al. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia. Ann Pharmacother. 2010;44(3):415-23.
Sansanayudh, N., Wongwiwatthananukit, S., Putwai, P., & Dhumma-Upakorn, R. (2010). Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia. The Annals of Pharmacotherapy, 44(3), 415-23. https://doi.org/10.1345/aph.1M522
Sansanayudh N, et al. Comparative Efficacy and Safety of Low-dose Pitavastatin Versus Atorvastatin in Patients With Hypercholesterolemia. Ann Pharmacother. 2010;44(3):415-23. PubMed PMID: 20179259.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia. AU - Sansanayudh,Nakarin, AU - Wongwiwatthananukit,Supakit, AU - Putwai,Pawat, AU - Dhumma-Upakorn,Rawadee, Y1 - 2010/02/23/ PY - 2010/2/25/entrez PY - 2010/2/25/pubmed PY - 2010/5/19/medline SP - 415 EP - 23 JF - The Annals of pharmacotherapy JO - Ann Pharmacother VL - 44 IS - 3 N2 - BACKGROUND: Previous studies have shown conflicting results on low-density lipoprotein cholesterol (LDL-C) reduction for comparable doses of pitavastatin and atorvastatin. OBJECTIVE: To compare the efficacy of pitavastatin 1 mg once daily with that of atorvastatin 10 mg once daily on lipoprotein change, safety, and cost per percent LDL-C reduction. METHODS: An 8-week, randomized, open-label, parallel trial was conducted in patients with hypercholesterolemia. One hundred patients were equally randomized to receive pitavastatin 1 mg once daily or atorvastatin 10 mg once daily; 98 completed the study. Outcomes were assessed at baseline and at the end of the study. RESULTS: Pitavastatin lowered LDL-C levels from baseline by 37% compared with 46% in the atorvastatin group (p < 0.001). The reduction of total cholesterol (TC) levels from baseline was significantly different between the pitavastatin (28%) and atorvastatin (32%) groups (p = 0.005). There was no significant difference in the percentage of changes in triglyceride and high-density lipoprotein cholesterol levels between groups. The percentage of patients who achieved LDL-C goals according to National Cholesterol Education Program-Adult Treatment Panel III guidelines was not significantly different between the pitavastatin (74%) and atorvastatin (84%) groups (p = 0.220). In addition, both regimens were well tolerated, with no patient developing an elevation of more than 3 times the upper normal limit of alanine aminotransferase or 10 times that of creatine kinase. The monthly cost per percent LDL-C reduction in the pitavastatin group ($0.77) was about 50% lower than the cost in the atorvastatin ($1.56) group. CONCLUSIONS: Although pitavastatin 1 mg daily was not as effective at lowering LDL-C and TC levels as atorvastatin 10 mg daily, the number of patients achieving their LDL-C goals with pitavastatin was comparable with the number using atorvastatin. Pitavastatin 1 mg once daily may be an alternative regimen with cost-saving benefits but without a significant decrease in therapeutic benefit or increase in adverse events in patients with hypercholesterolemia. SN - 1542-6270 UR - https://www.unboundmedicine.com/medline/citation/20179259/Comparative_efficacy_and_safety_of_low_dose_pitavastatin_versus_atorvastatin_in_patients_with_hypercholesterolemia_ L2 - https://journals.sagepub.com/doi/10.1345/aph.1M522?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -